Holen Sie sich die Stockscreener-App
0.6799
9.48%
-0.0712
Schlusskurs vom Vortag:
$0.7511
Offen:
$0.76
24-Stunden-Volumen:
1.55M
Relative Volume:
1.06
Marktkapitalisierung:
$2.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.64M
KGV:
-0.0982
EPS:
-6.9236
Netto-Cashflow:
$-10.11M
1W Leistung:
+6.47%
1M Leistung:
-15.01%
6M Leistung:
-70.57%
1J Leistung:
-66.00%
1-Tages-Spanne:
$0.6443
$0.765
1-Wochen-Bereich:
$0.64
$1.37
52-Wochen-Spanne:
$0.55
$4.10
Gt Biopharma Inc Stock (GTBP) Company Profile
Firmenname
Gt Biopharma Inc
Sektor
Branche
Telefon
(800) 304-9888
Adresse
505 MONTGOMERY STREET, SAN FRANCISCO
Vergleichen Sie GTBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
4.00 | 5.77B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.00 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.63 | 109.81M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.21 | 439.54M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
0.93 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Eingeleitet | ROTH MKM | Buy |
| 2021-05-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-13 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-17 | Eingeleitet | ROTH Capital | Buy |
Gt Biopharma Inc Aktie (GTBP) Neueste Nachrichten
Tools to assess GT Biopharma Inc.’s risk profile2025 Trading Volume Trends & Stock Timing and Entry Methods - newser.com
Will GT Biopharma Inc. continue its uptrendMarket Growth Report & Fast Momentum Stock Entry Tips - newser.com
GT Biopharma Inc OXIA Stock Analysis and ForecastEconomic Data Impact & Investment Recommendations You Can Trust - earlytimes.in
Chart based analysis of GT Biopharma Inc. trendsStop Loss & Weekly High Potential Stock Alerts - newser.com
Using economic indicators to assess GT Biopharma Inc. potentialMarket Growth Summary & Breakout Confirmation Alerts - newser.com
GT Biopharma Inc. stock volume spike explainedPortfolio Growth Summary & AI Driven Stock Reports - newser.com
Will GT Biopharma Inc. (OXIA) stock test record highs in 2025Quarterly Trade Report & Trade Opportunity Analysis Reports - newser.com
GT Biopharma Inc. stock trend forecastWeekly Profit Report & Fast Moving Market Watchlists - newser.com
Why GT Biopharma Inc. stock is seen as undervaluedPortfolio Performance Report & Long-Term Growth Portfolio Plans - newser.com
GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally - Stocktwits
Visual trend scoring systems applied to GT Biopharma Inc.Market Risk Summary & Long-Term Capital Growth Ideas - newser.com
Using data filters to optimize entry into GT Biopharma Inc.Insider Selling & Consistent Profit Alerts - newser.com
GT Biopharma advances Phase 1 trial of NK cell therapy with no safety issues - Investing.com Nigeria
Stocks In Play: GT Biopharma Inc - Barchart.com
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 - 富途牛牛
GT Biopharma provides enrollment update on GTB-3650 Phase 1 trial in patients with relapsed or refractory (R/R) CD33 expressing hematologic malignancies - MarketScreener
GT Biopharma Reports Successful Phase 1 Trial Progress for GTB-3650 in Hematologic Malignancies - Quiver Quantitative
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 - GlobeNewswire
GT Biopharma Initiates Cohort 3 Dosing; No DLTs, Cohort 4 Planned | GTBP Stock News - Stock Titan
EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers - Benzinga
GT Biopharma Inc - Menafn.com
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion - MarketScreener
Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms - Eastern Progress
Precision Oncology Pipeline Advances from Detection Through Targeted Destruction - The Globe and Mail
GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit - GlobeNewswire
Oct 28–29: GT Biopharma CEO Michael Breen to Attend Bahamas Summit; One-on-one Meetings Available - Stock Titan
Key metrics from GT Biopharma Inc.’s quarterly dataBond Market & Weekly Momentum Stock Picks - newser.com
How GT Biopharma Inc. (OXIA) stock reacts to new regulationsJuly 2025 Short Interest & Technical Entry and Exit Tips - newser.com
What’s the recovery path for long term holders of GT Biopharma Inc.Market Volume Summary & Expert Curated Trade Setups - newser.com
What drives GT Biopharma Inc stock priceChart Pattern Recognition & Small Capital Trading Growth - earlytimes.in
Will GT Biopharma Inc. (OXIA) stock profit from automation wave2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com
GT Biopharma Inc Stock Analysis and ForecastHead and Shoulders Patterns & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in
Can swing trading help recover from GT Biopharma Inc. lossesTrade Analysis Summary & AI Enhanced Market Trend Forecasts - newser.com
Finanzdaten der Gt Biopharma Inc-Aktie (GTBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):